You are here

  • Home
  • Archive
  • Volume 79, Issue 6
  • Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

Article metrics

Article menu

Download PDFPDF

Osteoarthritis
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

 

Online download statistics by month:

Online download statistics by month: March 2020 to March 2024

AbstractFullPdf
Mar 2020777712
Apr 202016841661529
May 2020874862334
Jun 2020667660305
Jul 2020411398185
Aug 2020240224108
Sep 2020253244156
Oct 2020182158198
Nov 2020206196129
Dec 2020217209107
Jan 2021335327163
Feb 2021348345157
Mar 2021416401162
Apr 202120019698
May 2021194179106
Jun 2021184179125
Jul 202111911874
Aug 2021200188130
Sep 2021210201103
Oct 2021197190142
Nov 2021168152100
Dec 202113312549
Jan 202213013057
Feb 202211810948
Mar 202216015078
Apr 202214414158
May 202213913780
Jun 202212011554
Jul 202212412576
Aug 202211511352
Sep 202214412159
Oct 202211610945
Nov 202211411756
Dec 2022878240
Jan 2023938843
Feb 202312511834
Mar 2023948140
Apr 2023746431
May 2023705945
Jun 2023735832
Jul 2023676030
Aug 2023685839
Sep 2023625622
Oct 2023615843
Nov 2023967935
Dec 202313511630
Jan 20241098138
Feb 2024795734
Mar 2024121100103
Total1035398724774